Market Scenario:
MRFR’s outlook towards the worldwide active pharmaceutical ingredient (API) market remains positive with a 4.93% CAGR forecast for the next five years. In terms of clinical efficacy and value, APIs have become an important component in the healthcare sector. The emergence of novel therapeutics coupled with development of advanced delivery systems is likely to create lucrative market opportunities for APIs in the forthcoming years. The growing trend towards personalized medicines is also influencing the API market landscape. In addition, increased focus towards reducing overall cost of manufacturing and supply chain consolidation are some of the other reasons behind the dramatic growth of APIs in recent years.
Segmentation
The segmental analysis of the market is based on the segments of the manufacturing process, API formulation, application, type of synthesis, molecule, and region. The market segmentation by type of synthesis consists of biotech and synthetic segments. The synthetic segment in 2017 was worth USD 132,690.7 Mn. The manufacturing process based segmentation of the market comprises of contract manufacturing and captive manufacturing. The captive manufacturing segment presently has the significant market share and is expected to remain extremely lucrative throughout the assessment period. The API formulation segments the market into innovative API and generic API. The generic API segment presently held the leading market share in 2017.

Regional Analysis
The market for APIs has been segmented into Europe, Americas, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas region presently controls the significant market portion, and the trend will probably carry on in the foreseeable future. This factor is majorly related to the robust value sustained by the small molecule segment in both Canada and the U.S. Additionally the pharmaceutical industry is among one of the major and most exceptional ventures in the US nations. The pharmaceutical organizations in the USA have developed quickly in comparison with other countries. The European and Asia Pacific region are also anticipated to continue growth in the revenue pockets for the active pharmaceutical ingredients (API) market during the forecast period. Europe accounts for the second largest market for active pharmaceutical ingredients which is followed by the Asia Pacific region. While the APAC region, the market’s course is mostly directed by factors such as the amplified level of expense on equipment and infrastructure, expanding initiatives which are motivating investment in APIs from drug makers to increase the capacity to produce APIs.
Key Players for global wireless health and fitness devices market
Sanofi, Bayer AG, Pfizer Inc., F. Hoffmann-La Roche AG, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc (GSK), Novartis AG, Eli Lilly and Company and Teva Pharmaceutical Industries Ltd. Profiles of the companies mentioned above are included in the report. Company profiling covered revenue analysis, segmental share, geographical dominance, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives.